Potential of ordered mesoporous silica for oral delivery of poorly soluble drugs

Therapeutic Delivery

Volumn 2, Issue 8, 2011, Pages 1079-1091

  Vialpando, Monica ^a   Martens, Johan A ^b   Van Den Mooter, Guy ^a  

^a DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

COK 11; CYCLODEXTRIN DERIVATIVE; FENOFIBRATE; HYDROXYPROPYLMETHYLCELLULOSE; HYDROXYPROPYLMETHYLCELLULOSE ACETATE SUCCINATE; IBUPROFEN; ITRACONAZOLE; MCM 41; ORDERED MESOPOROUS SILICA; SBA 15; SILICON DIOXIDE; UNCLASSIFIED DRUG;

BIOCOMPATIBILITY; CONTROLLED DRUG RELEASE; CRYSTALLIZATION; DISPERSION; DRUG ADSORPTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; ENCAPSULATION; HYDROPHILICITY; NANOSUSPENSION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SELF MICROEMULSIFYING DRUG DELIVERY SYSTEM; SUPERCRITICAL FLUID; SURFACE PROPERTY; SUSPENSION; THERMODYNAMICS;

EID: 80052408038     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.11.66     Document Type: Review

References (91)

1. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 3, 3-26 (2001). (Pubitemid 33653411)
2. Shen SC, Ng WK, Chia L, Dong YC, Tan RBH. Stabilized amorphous state of ibuprofen by co-spray drying with mesoporous SBA-15 to enhance dissolution properties. J. Pharm. Sci. 4, 1997-2007 (2010).
3. Kennedy T. Managing the drug discovery/development interfaces. Drug Disc. Today 46, 3-26 (1997).
4. Beck JS, Vartuli WJ, Roth ME et al. A new family of mesoporous molecular sieves prepared by liquid-crystal templates. J. Am. Chem. Soc. 114, 10834-10843 (1992).
5. Vallet-Regi M, Rámila A, del Real R P, Pérez-Pariente J. A new property of MCM-41: drug delivery system. Chem. Mater. 13, 308-311 (2001). (Pubitemid 32199334)
6. Tozuka Y, Oguchi T, Yamamoto K. Adsorption and entrapment of salicylamide molecules into the mesoporous structure of folded sheets mesoporous material (FSM-16). Pharm. Res. 6, 926-930 (2003). (Pubitemid 36628441)
7. Mellaerts R, Aerts CA, Van Humbeeck J, Augustijns P, Van den Mooter G, Martens JA. Enhanced release of itraconazole from ordered mesoporous SBA-15 silica materials. Chem. Commun. 13, 1375-1377 (2007). (Pubitemid 46465984)
8. Van Speybroeck M, Barillaro V, Thi TD et al. Ordered mesoporous silica material SBA-15: a broad-spectrum formulation platform for poorly soluble drugs. J. Pharm. Sci. 8, 2648-2658 (2009).
9. Thomas MJK, Slipper I, Walunj A et al. Inclusion of poorly soluble drugs in highly ordered meosoporous silica nanoparticles. Int. J. Pharm. 387, 272-277 (2010).
10. Ambrogi V, Perioli L, Marmottini F, Giovagnoli S, Esposito M, Rossi C. Improvement of dissolution rate of piroxican by inclusion into MCM-41 mesoporous silicate. Eur. J. Pharm. Sci. 32, 216-222 (2007). (Pubitemid 47532714)
11. Heikkilä T, Salonen J, Tuura J et al. Evaluation of mesoporous TCPSi, MCM-41, SBA-15 and TUD-1 materials as API carriers for oral drug delivery. Drug Deliv. 14, 337-347 (2007). (Pubitemid 47265819)
12. Mellaerts R, Mols R, Jammaer JAG et al. Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous material. Eur. J. Pharm. Biopharm. 69, 223-230 (2008).
13. Galarneau A, Nadar M, Guennaeu F, Di Renzo F, Gedeon A. Understanding the stability in water of mesoporous SBA-15 and MCM-41. J. Phys. Chem. C 111, 8268-8277 (2007). (Pubitemid 47012680)
14. Verlooy P, Aerts A, Levedev O, Van Tenderloo G, Kirschhock C, Martens JA. Synthesis of highly stable pure-silica thin-walled hexagonally ordered mesoporous material. Chem. Commun. 28, 4287-4289 (2009).
15. Charnay C, Bégu S, Tourné-Péteilh C, Nicole L, Lerner DA, Devoisselle JM. Inclusion of ibuprofen in mesoporous templated silica: drug loading and release properties. Eur. J. Pharm. Biopharm. 57, 533-540 (2004). (Pubitemid 38490572)
16. Zhao D, Feng J, Huo Q et al. Triblock copolymer syntheses of mesoporous silica with periodic 50-300 angstrom pores. Science 279, 548-552 (1998). (Pubitemid 28067280)
17. Kresge CT, Leonowitz ME, Roth WJ, Vartuli JC, Beck JS. Ordered mesoporous molecular sieves synthesized by liquid-crystal template mechanism. Nature 359, 710-712 (1992). (Pubitemid 23589384)
18. Kruk M, Jeroniec M. Characterization of the porous structure of SBA-15. Chem. Mater. 12, 1961-1968 (2000).
19. Galarneau A, Cambon H, Di Renzo F, Fajula F. True microporosity and surface area of mesoporous SBA-15 silicas as a function of synthesis temperature. Langmuir 17, 8328-8335 (2001) (Pubitemid 35330918)
20. Higuchi T Mechanism of sustained-action medication. J. Pharm. Sci. 52, 1145-1149 (1963).
21. Wang S. Ordered mesoporous materials for drug delivery. Micropor. Mesopor. Mater. 117, 1-9 (2009).
22. Andersson J, Rosenholm J, Areva S, Lindén M. Infuences of material characteristics on ibuprofen drug loading and release profles from ordered micro-and mesoporous silica matrices. Chem. Mater. 16, 4160-4167 (2004).
23. Horcajada P, Rámila A, Pérez-Pariente J, Vallet-Regí M. Infuence of pore size of MCM-41 matrices on drug delivery rate. Microporous Mesoporous Mater. 68, 105-109 (2004). (Pubitemid 38265756)
24. Van Speybroeck M, Mellaerts R, Mols R et al. Enhanced absorption of the poorly soluble drug fenofbrate by tunning its release rate from ordered mesoporous material. Eur. J. Pharm. Biopharm. 41, 623-630 (2010).
25. Sliwinska-Bartkowiak M, Dudziak G, Gras R, Sikorski R, Radhakrishnan R, Gubbins K. Freezing behavior in porous glasses and MCM-41. Colloid Surf A: Physiochem. Eng. Aspects 187-188, 523-529 (2001). (Pubitemid 32619185)
26. Schreiber A, Ketelson I, Findenegg GH. Melting and freezing of water in ordered mesoporous silica material. Phys. Chem. Chem. Phys. 3, 185-195 (2001).
27. Mellaerts R, Roeffaers MBJ, Houthoofd K et al. Molecular organization of hydrophobic molecules and co-adsorbed water in SBA-15 ordered mesoporous silica material. Phys Chem. Chem. Phys. 13, 2706-2713 (2010).
28. Mellaerts R, Houthoofd K, Elen K et al. Aging behavior of pharmaceutical formulations of itraconazole on SBA-15 ordered mesoporous silica carrier material. Microporous Mesoporous Mater. 130, 154-161 (2010).
29. Mellaerts R, Jammaer J, Van Spreybroeck M et al. Physical state of poorly water soluble therapeutic molecules loaded into SBA-15 ordered mesoporous silica carriers: a case study with itraconazole and ibuprofen. Langmuir 24, 8651-8659 (2008).
30. Izquierdo-Barba I, Martinez Á, Doadrio AL, Pérez-Pariente J, Vallet-Regi M. Release evaluation of drugs from ordered three-dimensional silica structures. Eur. J. Pharm. Sci. 26, 365-376 (2005).
31. Izquierdo-Barba I, Sousa E, Doadrio JC et al. Infuence of mesoporous structure type on the controlled delivery of drugs: release of ibuprofen from MCM-48, SBA-15 and functionalized SBA-15. J. Sol-Gel Technol. 50, 421-429 (2009).
32. Bals S, Batenburg J, Liang D et al. Quantitative three-dimensional modeling of zeolite through discrete electron tomography. J. Am. Chem. Soc. 131, 4769-4773 (2009).
33. Manzano M, Vallet-Regi M. New developments in ordered mesoporous materials for drug delivery. J. Mater. Chem. 20, 5593-5604 (2010).
34. Hata H, Saeki S, Kimura T, Sugahara Y, Kuroda K. Adsorption of Taxol into ordered mesoporous silicas with various pore diameters. Chem. Mater. 11, 1110-1119 (1999). (Pubitemid 129687282)
35. Carriazo D, Del Arco M, Fernández A, Martín C, Rives V. Inclusion and release of fenbufen in mesoporous silica. J. Pharm. Sci. 8, 3372-3380 (2010).
36. Belhadj-Ahmed F, Badens E, Llewellyn P, Denoyel R, Charbit G. Impregnation of vitamin E acetate on silica mesoporous phases using supercritical carbon dioxide. J. Supercrit. Fluids 51, 278-286 (2009).
37. Cassiers K, Linssen T, Mathieu M et al. A detailed study of thermal, hydrothermal, and mechanical stabilities of a wide range of surfactant assembled mesoporous silicas. Chem. Mater. 14, 2317-2324 (2002).
38. Jammaer J, Aerts A, D'Haen J, Seo JW, Martens JA. Convenient synthesis of ordered mesoporous silica at room temperature and quasi-neutral pH. J. Mater. Chem. 19, 8290-8293 (2009).
39. Vialpando M, Aerts A, Persoons J, Martens J, Van den Mooter G. Evaluation of ordered mesoporous silica as a carrier for poorly soluble drugs: infuence of pressure on the structure and drug release. J. Pharm. Sci. DOI: 10. 1002/JPS. 22535 (2011) (Epub ahead of print).
40. Janssens S, Van den Mooter G. Physical chemistry of solid dispersions. J. Pharm. Pharmacol. 61, 1571-1586 (2009).
41. Serajuddin ATM. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci. 10, 1058-1066 (1999).
42. Brouwers J, Brewster ME, Augustijns P. Supersaturating drug-delivery systems: the answer to solubility-limited oral bioavailability? J. Pharm. Sci. 8, 2549-2572 (2009).
43. Mellaerts R, Mols R, Kayaert P et al. Ordered mesoporous silica induces pH-independent supersaturation of the basic low solubility compound itraconazole resulting in enhanced transepithelial transport. Int. J. Pharm. 357, 169-179 (2008).
44. Janssens S, Van den Mooter G. Review: physical chemistry of solid dispersions. J. Pharm. Pharmacol. 61, 1571-1586 (2009).
45. Craig DQM. The mechanisms of drug release from solid dispersions in water-soluble polymers. Int. J. Pharm. 231, 131-144 (2002). (Pubitemid 34033673)
46. Janssens S, De Zeure A, Paudel A, Van Humbeeck J, Rombaut P, Van den Mooter G. Infuence of preparation methods on solid state supersaturation of amorphous solid dispersions: a case study with itraconazole and Eudragit E100. Pharm. Res. 5, 775-785 (2010).
47. Larson KL. Large cyclodextrins. J. Inclusion Phenom. Mol. Recog. Chem. 43, 1-13 (2002).
48. Woldum H, Larson KL, Madson F. Cyclodextrin controlled release of poorly water-soluble drugs from hydrogels. Drug Deliv. 15, 69-80 (2008).
49. Ueda H, Wakamiya T, Endo H, Nagase H, Tomono K, Nagai T. Ineraction of cyclomaltonoaose (delta-CD) with several drugs. Drug Dev. Ind. Pharm. 25, 951-954 (1999). (Pubitemid 29355120)
50. Mura P, Adragna E, Rabasco AM et al. Effects of the host cavity size and the preparation method on the physicochemical properties of ibuproxam- cyclodextrin systems. Drug Dev. Ind. Pharm. 25, 279-287 (1999). (Pubitemid 29108674)
51. Al Omari MM, El-Barghouthi MI, Zughul MB, Davies JED, Badwan AA. The role of drug hydrophobicity in b-cyclodextrin complexes. J. Mol. Liq. 155, 103-108 (2010).
52. Tros de Ilarduya MC, Martin C, Goni MM, Martinez-Oharriz MC. Solubilization and interaction of sulindac with b-cyclodextrin in the solid state and in aqueous media. Drug Dev. Ind. Pharm. 24, 301-306 (1998). (Pubitemid 28119250)
53. Zazycki PK, Lamparczyk H. The equilibrium constant of b-cyclodextrin-phenolphtalein complex; infuence of temperature and tetrahydrofuran addition. J. Pharm. Biomed. Anal. 18, 165-179 (1998).
54. Jain AC, Adeyeye MC. Hygroscopicity, phase solubility and dissolution of various substituted sulfobutylesther b-cyclodextrins (SBE) and danazol-SBE inclusion complexes. Int. J. Pharm. 212, 177-186 (2001). (Pubitemid 32119443)
55. Palmieri GF, Angeli DG, Giovannucci G, Martelli S. Inclusion of methoxytropate in b-and hydroxylpropyl b-cyclodextrins: comparison of prepation methods. Drug Dev. Ind. Pharm. 23, 27-37 (1997).
56. Moyano JR, Arias MJ, Fines JM, Perez JI, Rabasco AM. Dissolution behavior of oxazepam in the presence of cyclodextrins: evaluation of oxazepam dimeb binary systems. Drug Dev. Ind. Pharm. 23, 379-385 (1997). (Pubitemid 27186406)
57. Castillo JA, Palomo-Canales J, Garcia JJ, Lastres JL, Bolas F, Torrado JJ. Preparation and characterization of albendazole b-cyclodextrin complexes. Drug Dev. Ind. Pharm. 25, 1241-1248 (1999).
58. Diaz D, Escobar LCM, Bernad MJB. Study of the binding in an aqueous medium of inclusion complexes of several cyclodextrins involving fenoprofen calcium. Drug Dev. Ind. Pharm. 25, 107-110 (1999). (Pubitemid 29071494)
59. Loftsson T, Duchêne D. Cyclodextrins and their pharmaceutical applications. Int. J. Pharm. 329, 1-11 (2007). (Pubitemid 44937538)
60. Charman SA, Charman WN, Rogge MC, Wilson TD, Dutko FJ, Pouton CW. Self-emulsifying drug delivery systems: formulation and biopharmaceutical evaluation of an investigational lipophilic compound. Pharm. Res. 9, 87-93 (1992).
61. Constantinides PP. Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm. Res. 12, 1561-1572 (1995). (Pubitemid 26005509)
62. Kang BK, Lee JS, Chon SK et al. Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int. J. Pharm. 2004, 65-73 (2004). (Pubitemid 38457007)
63. Iwanaga K, Kushibiki T, Miyazaki M. Disposition of lipid-based formulation in the intestinal tract affects the absorption of poorly water-soluble drugs. Biol. Pharm. Bull. 3, 508-512 (2006).
64. Kyatanwar A, Jadhav KR, Kadam VJ. Self-microemulsifying drug delivery systems (SMEDDS): review. J. Pharm. Res. 1, 75-83 (2010).
65. Rao GCS, Kumar MS, Mathivanan N, Rao MEB. Nanosuspensions as the most promising approach in nanoparticulate drug delivery sytems. Pharmazie 59, 5-9 (2004). (Pubitemid 38129292)
66. Kocbek P, Baumgartner S, Kristl J. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. Int. J. Pharm. 312, 179-186 (2006).
67. Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 47, 3-19 (2001). (Pubitemid 32209229)
68. Fahr A, Liu X. Drug delivery strategies for poorly water-soluble drugs. Expert Opin. Drug Deliv. 4, 403-416 (2007). (Pubitemid 47249138)
69. Müller RH, Gohla S, Keck CM. State of the art of nanocrystals-special features, production, nanotoxicology aspects and intracellular delivery. Eur. J. Pharm. Biopharm. 78(1), 1-9 (2011).
70. Junghanns J, Müller RH. Nanocrystal technology, drug delivery and clinical applications. Int. J. Nanomedicine 3, 295-309 (2008).
71. Jacobs C, Kayser O, Müller RH. Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. Int. J. Pharm. 196, 161-164 (2000). (Pubitemid 30105734)
72. Shan N, Zaworotko MJ. The role of cocrystals in pharmaceutical science. Drug Disc. Today 13, 440-446 (2008).
73. Sekhon BS. Pharmaceutical co-crystals-a review. Ars. Pharm. 3, 99-117 (2009).
74. Trask AV. An overview of pharmaceutical co-crystals as intellectual property. Mol. Pharma 4, 301-309 (2007). (Pubitemid 46983946)
75. Blagden N, de Matas M, Gavan PT, York GP. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv. Drug Deliv. Rev. 59, 617-630 (2007). (Pubitemid 47285407)
76. Guzmán H, Tawa M, Zhang Z et al. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J. Pharm. Sci. 10, 2688-2702 (2007).
77. Gao P, Rush BD, Pfund WP et al. Development of a supersaturable SEDDS (S-Sedds) formulation of paclitaxel with improved oral bioavailability. J. Pharm. Sci. 12, 2386-2398 (2003). (Pubitemid 37484765)
78. Gao P, Guyton ME, Huang T, Bauer JM, Stefanski KJ, Qun L. Enhanced oral bioavailability of a poorly water soluble drug PNU-91325 by supersaturatable formulations. Drug Dev. Ind. Pharm. 2, 221-229 (2004). (Pubitemid 38420267)
79. Van Speybroeck M, Mols R, Mellaerts R et al. Combined use of ordered mesoporous silica and precipitation inhibitors for improved oral absorption of the poorly soluble weak base itraconazole. Eur. J. Pharm. Biopharm. 75, 354-365 (2010).
80. Aguilar F, Charrondiere U, Dusemund B et al. Calcium silicate and silicon dioxide/silicic acid gel added for nutritional purposes to food supplements. EFSA 1132, 1-24 (2009).
81. Hudson SP, Padera RF, Langer R, Kohane DS. The biocompatibility of mesoporous silicates. Biomaterials 29, 4045-4055 (2008).
82. Heikkilä T, Santos HA, Kumar N et al. Cytotoxicity study of ordered mesoporous silica MCM-41 and SBA-15 microparticles on caco-2 cells. Eur. J. Pharm. Biopharm. 74, 483-494 (2010).
83. Vallet-Regi M, Izquierdo-Barba I, Ramila A, Perez-Pariente J, Babonneau F, Gonzales-Calbet JM. Phosphorous-doped MCM-41 as bioactive material. Solid State Sci. 7, 233-237 (2005). (Pubitemid 40269524)
84. Carr RL. Evaluating fow properties of solids. Chem. Eng. 18-163 (1965).
85. Hausner HH. Friction conditions in a mass of metal powders. Int. J. Powder Metall. 3, 7-13 (1967).
86. Ishikawa T, Matsuda M, Yasukawa A et al. Surface silanol groups of mesoporous silica FSM-16. J. Chem. Soc. Faraday Trans. 11, 1985-1989 (1996). (Pubitemid 126789886)
87. Xu W, Gao Q, Xu Y, Wu D, Sun Y. pH-controlled drug release from mesoporous silica tablets coated with hydroxypropyle methylcellulose phthalate. Mat. Res. Bull. 44, 606-612 (2009).
88. Zürner A, Kirstein J, Döblinger M, Bräuchle C, Bein T. Visualizing single-molecule diffusion in mesoporous materials. Nature 450, 705-709 (2007).
89. Vallet-Regí M, Manzano M, González-Calbet JM, Okunishi E. Evidence of drug confnement into silica mesoporous matrices by STEM spherical aberration corrected microscopy. Chem. Commun. 46, 2956-2958 (2010).
90. Godec A, Gaberscek M, Jamnik J, Merzel F. Nonlinear diffusion in two-dimensional ordered porous media based on a free volume theory. J. Chem. Phys. 131, 234106-234112 (2009).
91. Sekiguchi K, Obi N. Studies on absorption of eutectic mixture. I. A comparison of the behavior of eutectic mixture of sulfathiazole and that of ordinary sulfathiazole in man. Chem. Pharm. Bull. 11, 866-872 (1961).